Pathological Complete Response (pCR) in Pancreatic Adenocarcinoma: Insights and Implications

Pathological complete response (pCR) following preoperative chemotherapy or chemoradiotherapy in patients with resected pancreatic adenocarcinoma is a rare but significant outcome. This retrospective, international, multicenter cohort study aimed to investigate the incidence, outcomes, and factors associated with pCR in patients with pancreatic adenocarcinoma.

Study Overview

• Study Design: This observational cohort study included 1758 patients with localized pancreatic adenocarcinoma who underwent resection after receiving preoperative chemotherapy (with or without radiotherapy) from January 1, 2010, to December 31, 2018.
• Objective: To assess the incidence of pCR, its association with overall survival (OS), and the factors contributing to pCR.

Key Findings

1. Incidence and Survival Outcomes:
   • The incidence of pCR was 4.8% (85 out of 1758 patients).
   • Patients with pCR had significantly better survival outcomes, with 1-, 3-, and 5-year OS rates of 95%, 82%, and 63%, respectively, compared to 80%, 46%, and 30% in patients without pCR.
2. Factors Associated with pCR:
   • Chemotherapy Regimens: Preoperative multiagent chemotherapy, especially modified FOLFIRINOX, was associated with higher pCR rates.
   • Radiotherapy: Preoperative conventional radiotherapy and stereotactic body radiotherapy (SBRT) were strongly associated with pCR, with SBRT showing a particularly strong association.
   • Biological Markers: Normalized serum carbohydrate antigen 19-9 (CA 19-9) levels post-therapy and partial or complete radiologic response were significant predictors of pCR.

Implications for Treatment Strategies

• Preoperative Therapy: The findings suggest that intensified preoperative regimens, particularly those including (m)FOLFIRINOX and SBRT, may enhance the likelihood of achieving pCR.
• Prognostication: Normalized CA 19-9 levels post-therapy can serve as an important prognostic marker, guiding clinical decisions for subsequent treatment.
• Future Research: Prospective studies are needed to validate these findings and explore the potential benefits of tailored preoperative therapies and adjuvant treatments in patients achieving pCR.

Conclusion

This study highlights the significant survival benefit associated with pCR in pancreatic adenocarcinoma and identifies key factors contributing to this outcome. The insights gained could inform treatment strategies and improve prognostication, ultimately enhancing patient outcomes.

For more detailed information, refer to the original study: JAMA Network Open, 2024;7(6)